Johnson & Higgins

MAIA Biotechnology, Inc., based in Chicago, IL, is focused on developing innovative cancer therapies through its pipeline of products currently under clinical investigation. The company's research emphasizes telomere targeting immunotherapies, including their lead program, Ateganosine, and several second-generation initiatives. Committed to advancing cancer treatment, MAIA Biotechnology's efforts are grounded in a scientific approach, although the safety and effectiveness of its products have yet to be established. The company's dedicated management team and advisory board guide its mission to innovate within the oncology landscape. Generated from the website

AltaThera Pharmaceuticals, based in Chicago, IL, is a precision medicine company dedicated to enhancing patient care through innovative science and individualized treatment solutions for cardiovascular drug therapy. With a focus on addressing the global arrhythmia epidemic, AltaThera is committed to bridging the gap between scientific innovation and clinical decision-making. The company's flagship product, Sotalol IV, represents a new formulation of a trusted antiarrhythmic drug that aims to streamline patient care by converting inpatient procedures to outpatient settings, ultimately reducing hospital stays. By leveraging clinical data to optimize the use of existing medications, AltaThera strives to improve treatment outcomes for diverse patient populations. Generated from the website

PellePharm, Inc., based in Chicago, IL, is a biotechnology company dedicated to targeting rare dermatological diseases, particularly Gorlin Syndrome and Basal Cell Carcinomas (BCCs), at their source. With a strong commitment to precision medicine, PellePharm aims to develop innovative treatments that enhance the quality of life for patients living with these conditions. The company is engaged in partnerships with organizations such as the Gorlin Syndrome Alliance and LEO Pharma to advance its research and development efforts. Currently, PellePharm is focused on patidegib, an investigational topical treatment designed to reduce tumor burden in patients affected by Gorlin Syndrome and BCCs, as there are no FDA-approved drugs available for this condition. Generated from the website